Medication info
Lopirel Tablet (Clopidogrel Sulfate)

Lopirel Tablet (Clopidogrel Sulfate)

Prescription medicationTabletOral
Ingredient · strength
Clopidogrel Bisulfate›97.875mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201306377 · Approved 2013.03.22 · Insurance code 648602500

Summary

Main use
Improvement of atherosclerotic conditions (such as acute coronary syndrome); prevention of thromboembolism in atrial fibrillation
Who takes it
Adults
Adult dose
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), initiate treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by an oral maintenance dose of 75 mg once daily. Aspirin 75 ~ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. Aspirin 75 ~ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be administered regardless of food intake.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of atherosclerotic conditions (such as acute coronary syndrome); prevention of thromboembolism in atrial fibrillation

  • Ischemic stroke
  • myocardial infarction
  • peripheral arterial disease
  • acute coronary syndrome
  • unstable angina
  • non-Q-wave myocardial infarction
  • cardiovascular abnormalities
  • stroke
  • refractory ischemia
  • vascular risk factors
  • bleeding risk
  • atrial fibrillation
View approved original text

This medication is helpful in improving symptoms in adult patients with atherosclerotic symptoms such as ischemic stroke, myocardial infarction, and peripheral arterial disease. It is also used to improve cardiovascular complications (such as myocardial infarction and stroke) in patients with acute coronary syndrome, particularly those with unstable angina or non-Q-wave myocardial infarction who are receiving or will receive drug treatment, coronary interventional procedures, or coronary artery bypass surgery. Additionally, it is effective in reducing the risk of stroke and thromboembolism in patients with atrial fibrillation who have vascular risk factors and where vitamin K antagonists are not suitable and the bleeding risk is low. This medication aids in reducing major cardiovascular risks and preventing thrombosis, thereby improving the patient's health status.

How to take

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), initiate treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by an oral maintenance dose of 75 mg once daily. Aspirin 75 ~ 325 mg should be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. Aspirin 75 ~ 100 mg should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be administered regardless of food intake.

Precautions

This medication is designed to prevent platelets in the blood from aggregating, thereby preventing the formation of blood clots. This medication must be converted to its active form in the liver for effectiveness; thus, individuals with genetically reduced function of the liver enzyme CYP2C19 may experience weakened efficacy. Therefore, in such cases, it is necessary to consult with a physician to adjust the treatment approach or to switch to another medication. Moreover, concomitant use with other medications that activate the CYP2C19 enzyme may increase the active ingredient concentration of this medication and elevate the risk of bleeding, so combination should be avoided. Patients who have allergies to this medication, those with severe bleeding, severe liver diseases, breastfeeding women, and those with lactose intolerance should not take this medication. If symptoms of bleeding occur during treatment, immediate consultation with a doctor is essential, especially for patients at risk of bleeding in delicate areas such as the gastrointestinal tract, brain, and eyes. Concomitant use with other platelet inhibitors or anticoagulants such as aspirin may further increase the risk of bleeding, thus caution is advised. Patients scheduled for surgery should discontinue use of this medication 5–7 days prior to the surgery and recommence only after hemostasis is achieved. This medication may rarely cause hematologic adverse reactions such as thrombocytopenia and neutropenia, so it is imperative to seek immediate consultation with a physician if symptoms of fever or infection arise. Mild side effects such as dyspepsia, diarrhea, headache, and rash may occur, and in cases of severe bleeding or allergic reactions, immediate medical attention is necessary. The risk to the fetus during pregnancy is not clearly defined, however, treatment should not be delayed for those with cardiovascular and cerebrovascular diseases, and caution is warranted as the risk of bleeding may increase during delivery. In breastfeeding cases, as this medication may be secreted into breast milk, the option to either cease breastfeeding or to discontinue the medication should be chosen. Elderly individuals or patients with impaired kidney or liver function are at increased risk of bleeding, hence careful observation and dosage adjustment should be undertaken. In cases of overdose, the risk of bleeding increases, and since there is no specific antidote, treatment such as platelet transfusion may be required in cases of severe bleeding. Store the medication out of reach of children and do not transfer it to another container. During treatment, any new medication initiation or surgery should be communicated to healthcare providers and any symptoms of bleeding should be reported immediately.

Side effects

  • Hemorrhage
  • gastrointestinal bleeding
  • purpura
  • contusion
  • hematoma
  • epistaxis
  • hematoma
  • hematuria
  • intraocular hemorrhage
  • intracranial hemorrhage
Show 90 more
  • severe neutropenia
  • aplastic anemia
  • severe thrombocytopenia
  • thrombocytopenia
  • rash
  • pruritus
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • headache
  • dizziness
  • chest pain
  • accidental injury
  • influenza-like illness
  • pain
  • fatigue
  • edema
  • hypertension
  • depression
  • upper respiratory tract infection
  • shortness of breath
  • rhinitis
  • bronchitis
  • cough
  • urinary tract infection
  • purpura
  • bloody stools
  • thrombocytopenia
  • anemia
  • pneumonia
  • sinusitis
  • eczema
  • skin ulcer
  • cystitis
  • cataract
  • conjunctivitis
  • allergic symptoms
  • ischemic necrosis
  • generalized edema
  • gastritis
  • hemorrhagic gastroenteritis
  • duodenal ulcer
  • gastric ulcer
  • perforated gastric ulcer
  • upper gastrointestinal tract bleeding
  • distension
  • hyperbilirubinemia
  • infectious hepatitis
  • fatty liver
  • hemorrhagic arthropathy
  • hematuria
  • hemoptysis
  • retroperitoneal hemorrhage
  • surgical wound bleeding
  • pulmonary hemorrhage
  • serum sickness
  • confusion
  • hallucinations
  • taste disturbances
  • loss of taste
  • vasculitis
  • hypotension
  • bronchospasm
  • interstitial pneumonia
  • eosinophilic pneumonia
  • colitis
  • pancreatitis
  • stomatitis
  • hepatitis
  • acute liver failure
  • maculopapular rash
  • urticaria
  • angioedema
  • vesicular dermatitis
  • drug-induced hypersensitivity syndrome
  • eosinophilia
  • drug rash
  • lichen planus
  • arthralgia
  • arthritis
  • myalgia
  • glomerulopathy
  • gynecomastia
  • fever
  • abnormal liver function test results
  • increased blood creatinine
  • cholecystitis
  • hematemesis
  • spinal hematoma

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is recommended to keep it at a temperature between 1 to 30 degrees Celsius. Storing it this way preserves the medication's effectiveness and prevents deterioration.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.